# EDGAR Filing Document

**Accession Number:** 0001410939
**File Stem:** 0001410939-23-000016
**Filing Date:** 2023-2
**Character Count:** 7372
**Document Hash:** 9585f256f8b38d2fc6c00eb98a908598
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001410939-23-000016.hdr.sgml**: 20230222

**ACCESSION NUMBER**: 0001410939-23-000016

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230217

**FILED AS OF DATE**: 20230222

**DATE AS OF CHANGE**: 20230222

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Westby Keith
- **CENTRAL INDEX KEY:** 0001696429

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36080
- **FILM NUMBER:** 23654933

**MAIL ADDRESS:**
- **STREET 1:** ONE UNIVERSITY SQUARE DRIVE, SUITE 280
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IVERIC bio, Inc.
- **CENTRAL INDEX KEY:** 0001410939
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 208185347
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 8 SYLVAN WAY
- **CITY:** PARSIPPANY
- **STATE:** NJ
- **ZIP:** 07054
- **BUSINESS PHONE:** (609) 474-6755

**MAIL ADDRESS:**
- **STREET 1:** 8 SYLVAN WAY
- **CITY:** PARSIPPANY
- **STATE:** NJ
- **ZIP:** 07054

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ophthotech Corp.
- **DATE OF NAME CHANGE:** 20070828

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Westby Keith<br><sub>(Last) (First) (Middle)</sub><br>C/O IVERIC BIO, INC.<br>8 SYLVAN WAY<br><sub>(Street)</sub><br>PARSIPPANY, NJ 07054<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-17 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_SVP, Chief Operating Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>IVERIC bio, Inc. [ ISEE ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-02-17 |  | M<sup>(1)</sup> |  | 3786 | A | $2.94 | 50140 | D |  |
| Common Stock | 2023-02-17 |  | S<sup>(1)</sup> |  | 3786 | D | 25.05<sup>(2)</sup> | 46354 | D |  |
| Common Stock | 2023-02-17 |  | M<sup>(1)</sup> |  | 11214 | A | $4.52 | 57568 | D |  |
| Common Stock | 2023-02-17 |  | S<sup>(1)</sup> |  | 11214 | D | 25.05<sup>(2)</sup> | 46354 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $2.94 | 2023-02-17 |  | M<sup>(1)</sup> |  |  | 3786 | <sup>(3)</sup> | 2027-12-18 | Common Stock | 3786.0 | $2.94 | 146214 | D |  |
| Stock Option (right to buy) | $4.52 | 2023-02-17 |  | M<sup>(1)</sup> |  |  | 11214 | <sup>(4)</sup> | 2027-01-29 | Common Stock | 11214.0 | $4.52 | 48786 | D |  |

---

### Footnotes:

(1) The sale reported on this form was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2022.

(2) The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $25.00 to $25.14 per share on February 17, 2023. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.

(3) This stock option award was granted on December 19, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.

(4) This stock option award was granted on January 30, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.

**Signature:** /s/ Todd D.C. Anderman, as Attorney-in-Fact for Keith Westby  
**Date:** 2023-02-22

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**